Effects of UGT1A1*28 polymorphism on raloxifene pharmacokinetics and pharmacodynamics

British Journal of Clinical Pharmacology

Volumn 67, Issue 4, 2009, Pages 437-444

  Trontelj, Jurij ^a   Marc, Janja ^a   Zavratnik, Andrej ^b   Bogataj, Marija ^a   Mrhar, Aleš ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

BMD; Osteoporosis; Polymorphism; Raloxifene; UGT1A1 28

Indexed keywords

BILIRUBIN; GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A1; RALOXIFENE; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BONE DENSITY CONSERVATION AGENT; GLUCURONOSYLTRANSFERASE;

AGED; ALLELE; ARTICLE; BONE DENSITY; CANCER PREVENTION; DRUG CLEARANCE; DRUG MECHANISM; DRUG METABOLISM; ENZYME SUBSTRATE COMPLEX; FEMALE; FEMUR; GENETIC POLYMORPHISM; HIP; HOMOZYGOSITY; HUMAN; LIQUID CHROMATOGRAPHY; LUMBAR SPINE; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; WILD TYPE; ADULT; DRUG EFFECT; GENETICS; MIDDLE AGED; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME;

ADULT; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POLYMORPHISM, GENETIC; RALOXIFENE; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 63849264200     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03363.x     Document Type: Article

References (30)

1. FDA News. FDA Approves New Uses for Evista. U.S. Department of Health & Human Services, 200 Independence Avenue, S.W. Washington, D.C. 20201, Sept. 2007.
2. NDA-020-815, U.S. Food and Drug Administration. 5600 Fishers Lane, Rockville MD 20857-0001, 1999. Available at http://www.fda.gov/cder/foi/nda/99/ 20815S3-Evista.htm (last accessed 10 February 2009).
3. Kemp DC, Fan PW, Stevens JC. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 2002 30 : 694 700.
4. Jeong EJ, Liu Y, Lin H, Hu M. Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab Dispos 2005 33 : 785 94.
5. Tukey RH, Strassburg CP. Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 2001 59 : 405 14.
6. Burchell B, Hume R. Molecular genetic basis of Gilbert's syndrome. J Gastroenterol Hepatol 1999 14 : 960 6.
7. Vasconcelos A. UGT1A1 genotyping and neutropenia risk. Lancet 2007 10 : 873.
8. Tallman MN, Ritter JK, Smith PC. Differential rates of glucuronidation for 7-ethyl-10-hydroxy-camptothecin (SN-38) lactone and carboxylate in human and rat microsomes and recombinant UDP-glucuronosyltransferase isoforms. Drug Metab Dispos 2005 33 : 977 83.
9. Boyd MA, Siangphoe U, Ruxrungtham K, Duncombe CJ, Stek M, Lange JM, Cooper DA, Phanuphak P. Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenet Genomics 2006 16 : 321 9.
10. Trontelj J, Bogataj M, Marc J, Mrhar A. Development and validation of a liquid chromatography-tandem mass spectrometry assay for determination of raloxifene and its metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007 855 : 220 7.
11. Ostanek B, Furlan D, Mavec T, Lukac-Bajalo J. UGT1A1(TA)n promoter polymorphism - a new case of a (TA)8 allele in Caucasians. Blood Cells Mol Dis 2007 38 : 78 82.
12. Jeong EJ, Liu X, Jia X, Chen J, Hu M. Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions. Curr Drug Metab 2005 6 : 455 68.
13. Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharmaceutics 2004 277 : 3 9.
14. Wu C-Y, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005 22 : 11 23.
15. Hochner-Celnikier D. Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gynecol Reprod Biol 1999 85 : 23 9.
16. Czock D, Keller F, Heringa M, Rasche FM. Raloxifene pharmacokinetics in males with normal and impaired renal function. Br J Clin Pharmacol 2005 59 : 479 82.
17. Dodge JA, Lugar CW, Cho S, Short LL, Sato M, Yang NN, Spangle LA, Martin MJ, Phillips DL, Glasebrook AL, Osborne JJ, Frolik CA, Bryant HU. Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity. J Steroid Biochem Mol Biol 1997 61 : 97 106.
18. Oswald S, Haenisch S, Fricke C, Sudhop T, Remmler C, Giessmann T, Jedlitschky G, Adam U, Dazert E, Warzok R, Wacke W, Cascorbi I, Kroemer HK, Weitschies W, von Bergmann K, Siegmund W. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther 2006 79 : 206 17.
19. Lin JP, O'Donnel CJ, Schwaiger JP, Cupples LA, Lingenhel A, Hunt SC, Yang S, Kronenberg F. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 2006 114 : 1476 81.
20. Peterkin VC, Bauman JN, Goosen TC, Menning L, Man MZ, Paulauskis JD, Williams JA, Myrand SP. Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes. Br J Clin Pharmacol 2007 64 : 458 68.
21. Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 2005 106 : 97 132.
22. Peterson S, Bigler J, Horner NK, Potter JD, Lampe JW. Cruciferae interact with the UGT1A1*28 polymorphism to determine serum bilirubin levels in humans. J Nutr 2005 135 : 1051 5.
23. Dorne JL, Walton K, Renwick AG. Human variability in glucuronidation in relation to uncertainty factors for risk assessment. Food Chem Toxicol 2001 39 : 1153 73.
24. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 2002 41 : 751 90.
25. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999 282 : 637 45.
26. Rosenfeld JA. Can the prophylactic use of raloxifene, a selective estrogen-receptor modulator, prevent bone mineral loss and fractures in women with diagnosed osteoporosis or vertebral fractures? West J Med 2000 173 : 186 7.
27. Peck P. High-dose raloxifene associated with reduced risk for cognitive impairment. Report from the 8th International Conference of Alzheimer's Disease and Related Disorders (July 20-25, 2002, Stockholm, Sweden). Available at http://www.docguide.com/news/content.nsf/news/8525697700573E1885256BFE006D83A5? OpenDocument&id=48DDE4A73E09A969852568880078C249&c=Alzheimer&count= 10 (last accessed 10 February 2009).
28. Shatalova EG, Loginov VI, Braga EA, Kazubskaia TP, Sudomoina MA, Blanchard RL, Favorova OO. Association of polymorphisms in SULT1A1 and UGT1A1 genes with breast cancer risk and phenotypes in Russian women. Mol Biol (Mosk) 2006 40 : 263 70.
29. Dalhoff K, Buus Jensen K, Enghusen Poulsen H. Cancer and molecular biomarkers of phase 2. Methods Enzymol 2005 400 : 618 27.
30. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006 355 : 125 37.